Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?
Yıl: 2018 Cilt: 43 Sayı: 5 Sayfa Aralığı: 481 - 486 Metin Dili: İngilizce DOI: 10.1515/tjb-2017-0238 İndeks Tarihi: 08-10-2019
Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?
Öz: Objective(s): Chromosomal abnormalities are more commonlyseen in embryos with decreased oocyte quality.Therefore aneuploidy due to diminished ovarian reservemay be one of the causative reasons of RPL. We investigatedthe relationship between ovarian reserve markers especiallyserum antimullerian hormone (AMH) level and antralfollicle count (AFC) and recurrent pregnancy loss (RPL).Materials and methods: This prospective cross-sectionalclinical trial including 88 women with RPL and 84 agematchedwomen without RPL.Results: There were statistically significant differencesin body mass index, live birth number, menstrual cyclelength, AFC and serum AMH level between groups. Therewas no statistically significant difference between groupsregarding age, menstrual cycle regularity and serum folliclestimulating hormone (FSH) and estradiol (E2) levels.The percentage of women with levels of AMH < 1 was21.4% in the RPL group and 11.4% in the control group.AFC <7 in both ovaries was lower in the RPL group whencompared with the control group (73.8% vs 44.3%,respectively).Conclusion(s): Serum AMH levels and AFC can be assessedin patients with RPL as a part of the work up parameters.Lower Serum AMH levels and AFC especially may predictthe quantity of oocytes that may be consequently berelated with RPL.
Anahtar Kelime: Konular:
Over rezerv belirteçleri tekrarlayan gebelik kaybı olan kadınlarda sonraki gebeliklerin sonuçlarını öngörür mü?
Öz: Amaç: Kromozomal anomaliler sıklıkla azalmış oosit kalitesi ile ilişkili gebeliklerin embriyolarında izlenmektedir. Dolayısıyla azalmış overyan rezerv ile ilişkili anöploidiler tekrarlayan gebelik kayıplarının bir nedeni (TGK) olabilir. Çalışmamızda over rezerv testleri özellikle de antimülleryan hormone (AMH) ve antral folikül sayısı (AFS) ile TGK arasındaki ilişkiyi incelemeyi amaçladık. Materyal ve Method: Prospektif cross-sectional olan çalışmamız 88 TGK öyküsü olan ve 84 TGK öyküsü olmayan kadın hastayı kapsamaktadır. Bulgular: Iki grup arasında vücut kitle indeksi (VKİ), canlı doğum sayısı, mesntrüel siklus uzunluğu, AFS ve serum AMH değeri açısından istatistiksel anlamlı fark bulundu. Yaş, menstrual siklus düzeni, serum folikül stimüle edici hormon ve östradiol değerleri açısından fark tespit edilmedi. AMH < 1 ng/mL, TGK grubunda %21.4 iken, kontrol grubunda %11.4 olarak hesaplandı. AFS < 7 olması, TGK grubunda kontrol grubuna gore daha yüksek oranda tespit edildi (%73.8 vs %44.3). Sonuç: AMH ve AFS, TGK olan hasta grubunda araştırma yapılırken bakılması gereken parametrelerden biri olabilir. Düşük AMH değeri ve AFS, azalmış oosit kalitesiyle ilişkili olup TGK ile sonuçlanabilir.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Practice Committee of American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril 2013;99:63.
- 2. Jauniaux E, Farquharson RG, Christiansen OB, Exalto N. Evidencebased guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod 2006;21:2216–22.
- 3. Yuan X, Lin HY, Wang Q, Li TC. Is premature ovarian ageing a cause of unexplained recurrent miscarriage? J Obstet Gynecol 2012;32:464–6.
- 4. Celik HG, Dogan E, Okyay E, Ulukus C, Saatli B, Uysal S, et al. Effect of laparoscopic excision of endometriomas on ovarian reserve: serial changes in the serum antimullerian hormone levels. Fertil Steril 2012;97:1472–8.
- 5. Tal R, Tal O, Seifer BJ, Seifer DB. Antimullerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertil Steril 2015;103:119–30.e3.
- 6. Lin PY, Huang FJ, Kung FT, Chiang HJ, Lin YJ, Lin YC, et al. Evaluation of serum anti-mullerian hormone as a biomarker of early ovarian aging in young women undergoing IVF/ICSI cycle. Int J Clin Exp Pathol 2014;7:6245–53.
- 7. Jirge PR. Ovarian reserve tests. J Hum Reprod Sci 2011;4:108–13.
- 8. Atasever M, Soyman Z, Demirel E, Gencdal S, Kelkci S. Diminished ovarian reserve: is it a neglected cause in the assessment of recurrent miscarriage? A cohort study. Fertil Steril 2016;105:1236–40.
- 9. Zarek SM, Mitchell EM, Sjaarda LA, Mumford SL, Silver RM, Stanford JB, et al. Antimullerian hormone and pregnancy loss from the effects of Aspirin in gestation and reproduction trial. Fertil Steril 2016;105:946–52.e2.
- 10. Grande M, Borobio V, Bennasar M, Stergiotou I, Mercade I, Masoller N, et al. Role of ovarian reserve markers, antimullerian hormone and antral follicle count, as aneuploidy markers in ongoing pregnancies and miscarriages. Fertil Steril 2015;103:1221–7.e2.
- 11. Zarek SM, Mitchell EM, Sjaarda LA, Mumford SL, Silver RM, Stanford JB, et al. Is anti-müllerian hormone associated with fecundability? Findings from the EAGeR trial. J Clin Endocrinol Metab 2015;100:4215–21.
- 12. Goswami M, Nikolaou D. Is AMH level, independent of age, a predictor of live birth in IVF? J Hum Reprod Sci 2017;10:24–30.
- 13. Szafarowska M, Molinska-Glura M, Jerzak MM. Anti-Müllerian hormone concentration as a biomarker of pregnancy success or failure. Neuro Endocrinol Lett 2014;35:322–6.
- 14. Su HI, Sammel MD, Homer MV, Bui K, Haunschild C, Stanczyk FZ. Comparability of antimullerian hormone levels among commercially available immunoassays. Fertil Steril 2014;101: 1766–72.e1.
- 15. Barad DH, Weghofer A, Gleicher N. Comparing anti- Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function. Fertil Steril 2009;91(Suppl4):S1553–5.
- 16. Morel N, Bachelot A, Chakhtoura Z, Ghillani-Dalbin P, Amoura Z, Galicier L, et al. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab 2013;98:3785–92.
- 17. Prakash A, Li TC, Laird S, Nargund G, Ledger WL. Absence of follicular phase defect in women with recurrent miscarriage. Fertil Steril 2006;85:1784–90.
- 18. Pils S, Promberger R, Springer S, Joura E, Ott J. Decreased ovarian reserve predicts inexplicability of recurrent miscarriage? A retrospective analysis. PLoS One 2016;11:e0161606.
| APA | YETKİN YILDIRIM G, ÇELİK H, köroğlu N, KARAKUŞ E (2018). Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?. , 481 - 486. 10.1515/tjb-2017-0238 |
| Chicago | YETKİN YILDIRIM Gonca,ÇELİK Hale GÖKSEVER,köroğlu Nadiye,KARAKUŞ ESRA Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?. (2018): 481 - 486. 10.1515/tjb-2017-0238 |
| MLA | YETKİN YILDIRIM Gonca,ÇELİK Hale GÖKSEVER,köroğlu Nadiye,KARAKUŞ ESRA Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?. , 2018, ss.481 - 486. 10.1515/tjb-2017-0238 |
| AMA | YETKİN YILDIRIM G,ÇELİK H,köroğlu N,KARAKUŞ E Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?. . 2018; 481 - 486. 10.1515/tjb-2017-0238 |
| Vancouver | YETKİN YILDIRIM G,ÇELİK H,köroğlu N,KARAKUŞ E Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?. . 2018; 481 - 486. 10.1515/tjb-2017-0238 |
| IEEE | YETKİN YILDIRIM G,ÇELİK H,köroğlu N,KARAKUŞ E "Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?." , ss.481 - 486, 2018. 10.1515/tjb-2017-0238 |
| ISNAD | YETKİN YILDIRIM, Gonca vd. "Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?". (2018), 481-486. https://doi.org/10.1515/tjb-2017-0238 |
| APA | YETKİN YILDIRIM G, ÇELİK H, köroğlu N, KARAKUŞ E (2018). Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?. Türk Biyokimya Dergisi, 43(5), 481 - 486. 10.1515/tjb-2017-0238 |
| Chicago | YETKİN YILDIRIM Gonca,ÇELİK Hale GÖKSEVER,köroğlu Nadiye,KARAKUŞ ESRA Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?. Türk Biyokimya Dergisi 43, no.5 (2018): 481 - 486. 10.1515/tjb-2017-0238 |
| MLA | YETKİN YILDIRIM Gonca,ÇELİK Hale GÖKSEVER,köroğlu Nadiye,KARAKUŞ ESRA Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?. Türk Biyokimya Dergisi, vol.43, no.5, 2018, ss.481 - 486. 10.1515/tjb-2017-0238 |
| AMA | YETKİN YILDIRIM G,ÇELİK H,köroğlu N,KARAKUŞ E Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?. Türk Biyokimya Dergisi. 2018; 43(5): 481 - 486. 10.1515/tjb-2017-0238 |
| Vancouver | YETKİN YILDIRIM G,ÇELİK H,köroğlu N,KARAKUŞ E Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?. Türk Biyokimya Dergisi. 2018; 43(5): 481 - 486. 10.1515/tjb-2017-0238 |
| IEEE | YETKİN YILDIRIM G,ÇELİK H,köroğlu N,KARAKUŞ E "Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?." Türk Biyokimya Dergisi, 43, ss.481 - 486, 2018. 10.1515/tjb-2017-0238 |
| ISNAD | YETKİN YILDIRIM, Gonca vd. "Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss?". Türk Biyokimya Dergisi 43/5 (2018), 481-486. https://doi.org/10.1515/tjb-2017-0238 |
